Regen BioPharma Inc
Regen BioPharma Inc is a U.S.-based biopharmaceutical development company organized in Nevada and operating through its wholly owned subsidiary KCL Therapeutics, Inc. The company focuses on regenerative medical applications and early-stage drug candidates, including small molecules aimed at NR2F6 for oncology and autoimmune disease research.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDevelopment-stage therapeutic applications intended for later-stage licensing or advancement.
Small-molecule and immune-activation candidates aimed at cancer applications.
Immune-cell suppression candidates designed for autoimmune indications.
Out-licensing or sale of developed applications after early clinical milestones.
Customers
Regen BioPharma does not appear to sell commercial products to a broad end-customer base; instead, its economic counterparties are typically potential licensees, strategic partners, and acquirers of drug candidates. In practice, the company’s “customers” are pharmaceutical or biotechnology organizations that may acquire rights to programs after preclinical or early clinical development. It also relies on capital providers and related-party funding to support development activities.
Buy rights to early-stage therapeutic programs after proof-of-concept or early clinical work.
Acquire developed applications or pipeline assets to add to their own portfolios.
Support discovery and development work around NR2F6 and related immune pathways.
Provide debt or equity funding that enables ongoing development and corporate operations.
Strategy
The company’s strategy is to identify and develop regenerative and immunology-related therapeutic candidates through early clinical milestones, then monetize them through licensing or sale. This model reduces the need to build a full commercial infrastructure, but it depends on successful scientific validation, regulatory progress, and partner interest. The company also seeks external financing to fund development until assets can be advanced or monetized.
Clinical and scientific validation is needed before any licensing or sale value can be realized.
Licensing or sale can convert development work into value without building a commercial sales force.
Development-stage biotech requires ongoing capital before product revenue is available.
Geography
Regen BioPharma is headquartered in the United States and is organized under Nevada law, with office operations referenced in California. Its business is primarily U.S.-based, and the available disclosures do not indicate meaningful international revenue concentration. Geography matters mainly through U.S. regulatory oversight, clinical development requirements, and access to domestic capital markets.
Risks
Regen BioPharma faces the typical risks of an early-stage biotech company: clinical failure, regulatory delay, and uncertainty that any candidate will reach commercialization or attract a partner. The company also has going-concern and financing risk because it depends on external capital and related-party support to continue operations. As a development-stage issuer, its reported results can be highly sensitive to small changes in financing, legal structure, and accounting estimates.
The company states it may need additional equity or debt financing to support working capital and operations.
Exposure: Corporate operations
Therapeutic candidates are early-stage and must clear preclinical and FDA hurdles before value can be realized.
Exposure: Pipeline programs
The business model depends on finding buyers or licensees for early-stage assets after development milestones.
Exposure: Licensing strategy
Funding and facilities are tied to the CEO and related entities, increasing dependence on a small group of counterparties.
Exposure: Financing and operations
Accounting
Judgemental itemsManagement discloses substantial doubt about the company’s ability to continue without additional funding.
Impact: Affects asset/liability classification and investor assessment of solvency
The company has issued and converted notes, which can change leverage and equity balances.
Impact: Can create noncash financing items and dilution
Notes payable and office arrangements involve the CEO and related entities.
Impact: Important for transparency, valuation, and governance analysis
Development costs are expensed as incurred in early-stage biotech models.
Impact: Drives reported losses before any product revenue exists
Similar listed companies
Publicly listed companies with a comparable business focus.
Regencell Bioscience Holdings Ltd
RGC · Medicinal Chemicals & Botanical Products
Regencell Bioscience Holdings Ltd is a Hong Kong-based bioscience company focused on developing botanical and medicinal chemical formulations.
Regeneron Pharmaceuticals, Inc
REGN · Pharmaceutical Preparations
Regeneron Pharmaceuticals is a U.S.-based biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious diseases.
Vincerx Pharma, Inc.
Pharmaceutical Preparations
Generation Bio Co.
Pharmaceutical Preparations
REGENXBIO Inc.
RGNX · Biological Products, (No Diagnostic Substances)
Regenerex Pharma, Inc.
Pharmaceutical Preparations
Last updated: 29/04/2026